Dr Feigin discusses findings from a study on the varying effects of the benzodiazepines lorazepam and alprazolam on progression-free survival outcomes for patients with pancreatic cancer.
Retrospective Study Associates Alprazolam With Improved PFS in Pancreatic Cancer
Michael Feigin, PhD, discusses data from a retrospective study investigating the association between benzodiazepines and survival outcomes in patients with pancreatic cancer.
The benzodiazepines lorazepam and alprazolam had differing effects on progression-free survival (PFS) outcomes among patients with pancreatic cancer, with lorazepam demonstrating an association with decreased PFS and alprazolam prolonging PFS.
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5